Distinguished in Astrocytoma

Catherine A. Mcbain

The Christie NHS FT
Manchester, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Astrocytoma
The Christie NHS FT
Manchester, ENG, GB 
OverviewLocationsClinical Research

Overview

Catherine Mcbain practices in Manchester, United Kingdom. Ms. Mcbain is rated as a Distinguished expert by MediFind in the treatment of Astrocytoma. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

Her clinical research consists of co-authoring 40 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 19 articles and participated in 2 clinical trials in the study of Astrocytoma.

Gender
Female

Locations

The Christie NHS FT
Manchester, ENG, United Kingdom
Other Locations
Wilmslow Rd, Manchester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients with Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship
A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients with Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship
Enrollment Status: Recruiting
Publish Date: December 13, 2024
Intervention Type: Other
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.
Enrollment Status: Active_not_recruiting
Publish Date: May 31, 2024
Intervention Type: Radiation, Drug
Study Drugs: 2-hydroxyoleic Acid, Temozolomide
Study Phase: Phase 2/Phase 3
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
Enrollment Status: Completed
Publish Date: February 05, 2018
Intervention Type: Drug, Procedure, Genetic, Other
Study Phase: Phase 1
View 4 Less Clinical Trials

40 Total Publications

Radiotherapy for Growing Vestibular Schwannomas.
Radiotherapy for Growing Vestibular Schwannomas.
Journal: JAMA otolaryngology-- head & neck surgery
Published: September 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mcbain's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile